Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

29. Dezember 2020 08:05 ET | Quelle: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces $5.0 Million Registered Direct Offering

SAN DIEGO, Dec. 29, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
22. Dezember 2020 08:05 ET | Quelle: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces $8.8 Million Registered Direct Offering

SAN DIEGO, Dec. 22, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
10. Dezember 2020 08:05 ET | Quelle: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces Dosing of First Patient in ENVASARC Pivotal Trial

SAN DIEGO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
23. November 2020 08:05 ET | Quelle: TRACON Pharmaceuticals, Inc.

TRACON Announces Publication in Cancer Cell of Clinical Data that Provides Molecular Insight into the Mechanism of Action of TRC102 and Patient Populations Most Likely to Respond to Treatment

SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
16. November 2020 09:45 ET | Quelle: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces Submission for Approval of Envafolimab (KN035) with the NMPA in China by its Corporate Partners Alphamab Oncology and 3D Medicines

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
10. November 2020 16:03 ET | Quelle: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
03. November 2020 08:05 ET | Quelle: TRACON Pharmaceuticals, Inc.

TRACON to Report Third Quarter 2020 Financial Results and Company Highlights on November 10, 2020

SAN DIEGO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
26. Oktober 2020 08:05 ET | Quelle: TRACON Pharmaceuticals, Inc.

TRACON Announces FDA Orphan Drug Designation for TRC102 in Malignant Glioma, Including Glioblastoma

SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
21. September 2020 08:05 ET | Quelle: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Highlights Updated Envafolimab Clinical Results in MSI-H/dMMR Colorectal Cancer

SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
10. September 2020 08:05 ET | Quelle: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

SAN DIEGO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...

Vorherige Seite

Nächste Seite